Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial

Table 3 Pulmonary Structural and Functional Characteristics of Patients with Lymphangioleiomyomatosis

Value	Baseline (n = 6)	12 months (n = 6)	24 months (n = 5)	Change from Baseline
Value	Baseline (n = 6)	12 months (n = 6)	24 months (n = 5)	12 months (n = 6)	24 months (n = 5)
FEV1
Least-square mean — liters	1.59 ± 0.41	1.87 ± 0.47	1.65 ± 0.45	0.28 ± 0.08 (P<0.001)	0.13 ± 0.05 (P = 0.004)
Percent of predicted value	58.51 ± 11.09	65.32 ± 12.32	59.89 ± 11.58	6.81 ± 2.28 (P<0.001)	3.46 ± 1.57 (P = 0.008)
FVC
Least-square mean — liters	2.77 ± 0.56	3.20 ± 0.68	2.95 ± 0.66	0.43 ± 0.17 (P = 0.002)	0.27 ± 0.14 (P = 0.013)
Percent of predicted value	79.90 ± 12.68	87.16 ± 12.63	84.36 ± 13.71	7.26 ± 2.16 (P<0.001)	6.39 ± 1.36 (P<0.001)
Total lung capacity
Least-square mean — liters	5.16 ± 0.51	5.18 ± 0.44	5.14 ± 0.49	0.03 ± 0.12 (P = 0.62)	0.04 ± 0.10 (P = 0.43)
Percent of predicted value	99.21 ± 7.01	99.70 ± 7.28	97.75 ± 7.24	0.49 ± 1.47 (P = 0.45)	−0.22 ± 0.78 (P = 0.57)
Residual volume
Least-square mean — liters	2.39 ± 0.10	1.98 ± 0.31	2.11 ± 0.29	−0.41 ± 0.24 (P = 0.009)	−0.31 ± 0.23 (P = 0.036)
Percent of predicted value	124.56 ± 10.04	104.23 ± 8.85	112.30 ± 5.41	−20.32 ± 1.62 (P<0.001)	−15.79 ± 2.38 (P<0.001)
DLco
Least-square mean — ml/mmHg/min	12.93 ± 2.42	13.00 ± 2.41	12.59 ± 2.39	0.07 ± 0.46 (P = 0.71)	−0.21 ± 0.55 (P = 0.43)
Percent of predicted value	53.40 ± 9.29	53.60 ± 8.70	54.27 ± 9.56	0.19 ± 1.39 (P = 0.74)	1.68 ± 2.11 (P = 0.15)

Data are listed for 6 patients with lymphangioleiomyomatosis who completed the 12-month study visit. Data for the 24-month study visit were available for 5 of these 6 patients; 1 patient had withdrawn during the second year. Changes from baseline were not significant unless otherwise indicated. DLco denotes diffusing capacity of the lung for carbon monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity

ISSN: 1750-1172